



## LabPas CT Selected by Nucleus Network for Phase I Clinical Trials

**Montpelier, Vermont**, April 30, 2007 — Nucleus Network, an internationally renowned clinical research center located in Melbourne, Australia, has selected LabPas CT to fully automate their Phase I clinical trials.

According to Andrew Giddy, CEO of Nucleus Network, "LabPas CT's comprehensive automation of the Phase I laboratory, clinic floor, recruiting, and sample storage enhances our commitment to provide sponsors with operational and service excellence by increasing compliance and speeding trials. It also helps position our new 24-bed, state-of-the-art Phase I facility as the preeminent clinical research center in Australia."

John Rosenblum, CEO of Green Mountain Logic, the developer of LabPas CT, added, "Nucleus Network is a very important partner for us. They are held in high regard by pharmaceutical and biotechnology sponsors throughout the world, and have very generously agreed to act as a LabPas CT demonstration site for Australia and Asia."

Nucleus Network is one of six highly regarded clinical research organizations in the past year – and one of two international clinics in the last month – to select LabPas CT. Others include CEDRA Clinical Research, Acclaim Pharma Research, Advanced Biomedical Research, Arkansas Clinical Research and a major Midwest health care facility.

LabPas CT, the leading software solution for Phase I clinical trials, improves margins, decreases liability and increases clinical capabilities. LabPas CT is unique in its intuitive use and adaptability to individual study protocols.

Nucleus Network conducts clinical research for national and international companies, acts as a drug development advisor to many smaller biotech companies and delivers education in Good Clinical Practice through a collaboration with the Association of Clinical and Research Professionals (ACRP). Nucleus Network provides a broad range of expertise on clinical research and product development to the global pharmaceutical, biotechnology and medical device industries through:

- A dedicated, self contained, state-of-the-art, 24-bed clinical trial unit with additional access to a full teaching hospital environment.
- The conduct of clinical trials (Phases I-III) with a specialized focus on early phase and First-in-Man studies.
- Collaboration with specialist investigators to conduct First-in-Patient studies.
- Clinical research consulting, focusing on entry to clinical development.
- Network partners, including all services, infrastructure and knowledge along the product development chain.

Nucleus Network will open a second purpose-built facility at the end of 2007 which will also utilize LabPas CT technology.

To learn more about Nucleus Network visit [www.nucleusnetwork.com.au](http://www.nucleusnetwork.com.au).

To learn more about LabPas CT visit [www.labpas.com](http://www.labpas.com).

### Contact

Patricia Sears, Vice President of Marketing  
Green Mountain Logic  
T: 1-866-LabPAS1  
E: [psears@gmlogic.com](mailto:psears@gmlogic.com)

## COMPREHENSIVE PHASE I SOFTWARE SYSTEM